Changes in Serum MicroRNAs after Anti-IL-5 Biological Treatment of Severe Asthma.
Manuel J RialJosé Antonio CañasJosé Manuel Rodrigo-MuñozMarcela Valverde-MongeBeatriz SastreJoaquín SastreVictoria Del PozoPublished in: International journal of molecular sciences (2021)
There is currently enough evidence to think that miRNAs play a role in several key points in asthma, including diagnosis, severity of the disease, and response to treatment. Cells release different types of lipid double-membrane vesicles into the extracellular microenvironment, including exosomes, which function as very important elements in intercellular communication. They are capable of distributing genetic material, mRNA, mitochondrial DNA, and microRNAs (miRNAs). Serum miRNA screening was performed in order to analyze possible changes in serum miRNAs in 10 patients treated with reslizumab and 6 patients with mepolizumab after 8 weeks of treatment. The expression of miR-338-3p was altered after treatment (p < 0.05), although no significant differences between reslizumab and mepolizumab were found. Bioinformatic analysis showed that miR-338-3p regulates important pathways in asthma, such as the MAPK and TGF-β signaling pathways and the biosynthesis/degradation of glucans (p < 0.05). However, it did not correlate with an improvement in lung function. MiRNA-338-3p could be used as a biomarker of early response to reslizumab and mepolizumab in severe eosinophilic asthmatic patients. In fact, this miRNA could be involved in airway remodeling, targeting genes related to MAPK and TGF-β signaling pathways.
Keyphrases
- lung function
- signaling pathway
- mitochondrial dna
- chronic obstructive pulmonary disease
- induced apoptosis
- stem cells
- copy number
- cystic fibrosis
- air pollution
- oxidative stress
- pi k akt
- genome wide
- epithelial mesenchymal transition
- gene expression
- newly diagnosed
- ejection fraction
- early onset
- transforming growth factor
- binding protein
- transcription factor
- fatty acid
- endoplasmic reticulum stress
- bone marrow
- combination therapy
- patient reported outcomes
- cell cycle arrest
- patient reported